Summary
Becton Dickinson and Company (BDX) reported its Q3 2013 results, showing a modest revenue increase of 3.6% year-over-year to $2.05 billion. This growth was primarily driven by volume increases, with contributions from the Medical and Diagnostics segments, bolstered by new product sales and acquisitions. However, the company experienced unfavorable foreign currency translation impacts which partially offset revenue gains. Net income for the quarter was $301.6 million, a slight decrease from $326.9 million in the prior year, resulting in diluted EPS of $1.52, down from $1.59. The decrease in profitability was influenced by a $22 million charge related to a settlement in an antitrust class action lawsuit and a $13 million charge for the U.S. medical device excise tax. Despite these headwinds, the company's financial position remains strong, with significant operating cash flows and substantial cash reserves.
Financial Highlights
50 data points| Revenue | $2.05B |
| Cost of Revenue | $993.00M |
| Gross Profit | $1.06B |
| R&D Expenses | $121.00M |
| SG&A Expenses | $534.00M |
| Operating Expenses | $1.65B |
| Operating Income | $405.00M |
| Interest Expense | $35.00M |
| Net Income | $301.55M |
| EPS (Basic) | $1.55 |
| EPS (Diluted) | $1.52 |
| Shares Outstanding (Basic) | 194.88M |
| Shares Outstanding (Diluted) | 198.72M |
Key Highlights
- 1Revenue increased by 3.6% to $2.05 billion, driven by volume growth and acquisitions, though partially offset by unfavorable foreign currency translation.
- 2Net income decreased to $301.6 million from $326.9 million in the prior year, impacting diluted EPS to $1.52 from $1.59.
- 3A $22 million settlement charge for antitrust class action litigation and a $13 million charge for the U.S. medical device excise tax impacted quarterly results.
- 4The Medical segment showed strong revenue growth (6.6%), supported by international sales and safety-engineered products.
- 5The Diagnostics segment experienced a 2.0% revenue increase, primarily driven by Preanalytical Systems.
- 6The Biosciences segment saw a 4.2% decrease in revenue due to weaker European sales and timing of orders.
- 7The company generated $989 million in net cash from continuing operating activities for the first nine months of the fiscal year, indicating strong operational cash generation.